Evidence map›Paper›PMID 30421494›Full record

ArticleBritish journal of clinical pharmacology2019

Reply to 'Overuse or underuse of methylphenidate in adults in France: commentary on Pauly et al. 2018' by Weibel et al.

Vanessa Pauly, Elisabeth Frauger, Marion Lepelley, Michel Mallaret, Quentin Boucherie, Joelle Micallef

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Vanessa PaulyLaboratoire de santé publique EA 3279, CEReSS-Centre d'Etudes et de Recherche sur les services de santé et la qualité de vie, Centre d'évaluation de la pharmacodépendance-addictovigilance (CEIP-A) de Marseille (PACA Corse) associé, Faculté de médecine, Aix-Marseille Université, Marseille, France.ORCID 0000-0003-1346-1781
Elisabeth FraugerService de pharmacologie clinique et pharmacovigilance, CNRS, CEIP-addictovigilance PACA Corse, INSERM 1106, Institut des neurosciences des systemes, CHU Timone, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France.
Marion LepelleyCentre d'Addictovigilance (CEIP) de Grenoble, Pavillon E CHU, Grenoble, France.
Michel MallaretCentre d'Addictovigilance (CEIP) de Grenoble, Pavillon E CHU, Grenoble, France.
Quentin BoucherieService de pharmacologie clinique et pharmacovigilance, CNRS, CEIP-addictovigilance PACA Corse, INSERM 1106, Institut des neurosciences des systemes, CHU Timone, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France.
Joelle MicallefService de pharmacologie clinique et pharmacovigilance, CNRS, CEIP-addictovigilance PACA Corse, INSERM 1106, Institut des neurosciences des systemes, CHU Timone, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MethylphenidateAdultChildFranceHumansMethylphenidate

Identifiers

PMID30421494
PMCPMC6303209

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.